Insulin‐like growth factor II messenger RNA‐binding protein‐3 is an independent prognostic factor in uterine leiomyosarcoma

Insulin‐like growth factor II messenger RNA‐binding protein‐3 is an independent prognostic... IntroductionUterine leiomyosarcoma (ULMS) is an uncommon smooth muscle tumour, accounting for approximately 1–2% of all uterine malignancies. Overall 5‐year survival rates range from 15 to 25% for all stages of ULMS. The mechanisms of tumorigenesis, pathogenesis and progression have not been well established. Disease stage has been shown to be the most important prognostic factor in ULMSs. Several series have found older age, large tumour size, non‐conventional subtype, high mitotic index, high‐grade cytological atypia, presence of coagulative tumour cell necrosis (CTN), low expression of hormone receptors and high expression of cell cycle markers to be significant predictors of poor outcomes, whereas other series have denied their prognostic significance.The mediator complex subunit 12 (MED12) gene on Xq13.1 encodes the MED12 protein, which participates in various molecular pathways; for example, the p53 and Wnt/β‐catenin pathways, which have central roles in tumour development. MED12 mutations were identified in several tumours, including colorectal cancer, prostate cancer, breast fibroadenoma and phyllodes tumours. In breast fibroepithelial tumours, MED12 mutations are detected more frequently in fibroadenomas and benign phyllodes tumours compared to malignant phyllodes tumours. As this gene mutation in leiomyomas was described first in 2011 by Makinen et al. in uterine smooth muscle tumours, numerous http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Histopathology Wiley

Insulin‐like growth factor II messenger RNA‐binding protein‐3 is an independent prognostic factor in uterine leiomyosarcoma

Loading next page...
 
/lp/wiley/insulin-like-growth-factor-ii-messenger-rna-binding-protein-3-is-an-sNH4aETuXC
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 John Wiley & Sons Ltd
ISSN
0309-0167
eISSN
1365-2559
D.O.I.
10.1111/his.13422
Publisher site
See Article on Publisher Site

Abstract

IntroductionUterine leiomyosarcoma (ULMS) is an uncommon smooth muscle tumour, accounting for approximately 1–2% of all uterine malignancies. Overall 5‐year survival rates range from 15 to 25% for all stages of ULMS. The mechanisms of tumorigenesis, pathogenesis and progression have not been well established. Disease stage has been shown to be the most important prognostic factor in ULMSs. Several series have found older age, large tumour size, non‐conventional subtype, high mitotic index, high‐grade cytological atypia, presence of coagulative tumour cell necrosis (CTN), low expression of hormone receptors and high expression of cell cycle markers to be significant predictors of poor outcomes, whereas other series have denied their prognostic significance.The mediator complex subunit 12 (MED12) gene on Xq13.1 encodes the MED12 protein, which participates in various molecular pathways; for example, the p53 and Wnt/β‐catenin pathways, which have central roles in tumour development. MED12 mutations were identified in several tumours, including colorectal cancer, prostate cancer, breast fibroadenoma and phyllodes tumours. In breast fibroepithelial tumours, MED12 mutations are detected more frequently in fibroadenomas and benign phyllodes tumours compared to malignant phyllodes tumours. As this gene mutation in leiomyomas was described first in 2011 by Makinen et al. in uterine smooth muscle tumours, numerous

Journal

HistopathologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from Google Scholar, PubMed
Create lists to organize your research
Export lists, citations
Access to DeepDyve database
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off